Recombinant P53 adenovirus methods and compositions

Details Recombinant P53 adenovirus methods and compositions Recombinant P53 adenovirus methods and compositions

2006-04-25

2006-04-25

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S069100, C435S320100, C435S455000, C435S456000, C435S325000, C435S366000, C435S369000, C435S235100, C435S239000

Reexamination Certificate

active

07033750

ABSTRACT:
Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.

REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5055400 (1991-10-01), Lo et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5496731 (1996-03-01), Xu et al.
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5763209 (1998-06-01), Sukhatme
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6090566 (2000-07-01), Vogelstein et al.
patent: 6143290 (2000-11-01), Zhang et al.
patent: 6210939 (2001-04-01), Gregory et al.
patent: 6410010 (2002-06-01), Zhang et al.
patent: 6511847 (2003-01-01), Zhang et al.
patent: 6677312 (2004-01-01), Vogelstein et al.
patent: 6800617 (2004-10-01), Vogelstein et al.
patent: 0174608 (1985-09-01), None
patent: 0351585 (1989-06-01), None
patent: 0390323 (1990-10-01), None
patent: 0475623 (1991-08-01), None
patent: 2688514 (1993-09-01), None
patent: 4-9338 (1992-01-01), None
patent: WO 90/05180 (1990-05-01), None
patent: WO 90/10448 (1990-09-01), None
patent: WO 91/15580 (1991-10-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/11301 (1995-04-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14101 (1995-05-01), None
patent: WO 95/14102 (1995-05-01), None
patent: WO 95/23867 (1995-09-01), None
patent: WO 95/30002 (1995-11-01), None
Anderson, “Human Gene Therapy,”Nature, 392:25-30, Apr. 30, 1998.
Bacchetti, et al, “Inhibition of Cell Proliferation by and Adenovirus Vector Expressing the Human Wild Type p53 Protein,”International Journal of Oncology, 3:781-788, 1993.
Baker et al., “Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carinomas,”Science, 244:217-221, Apr. 1989.
Baker et al., “p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis,”Cancer Research, 50:7717-7722, Dec. 1990.
Baker et al., “Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53,”Science, 249:912-915, Aug. 1990.
Bandyopadhyay and Temin, “Expression of Complete Chicken Thymidine Kinase Gene Inserted in a Tetrovirus Vector,”Molecular and Cellular Biology, 4(4):749-754, 1984.
Bargonetti et al., “Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication,”Cell, 65:1083-1091, 1991.
Berkner, “Development of adenovirus vectors for the expression of heterologous genes”,BioTechniques, 6(7):616-629, 1988.
Blenis, “Signal transduction via the MAP kinases: Proceed at your own RSK”,Proc. Natl. Acad. Sci. USA, 90:5889-5892, 1993.
Bowtell et al., “Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes,”Journal of Virology, 62(7):2464-2473, 1988.
Brachman et al., “p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines”,Cancer Res., 53:3667-3669, 1993.
Brown et al., “Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines,”Int. J. Cancer, 55:678-684, 1993.
Brown et al., “Mutant p53 confers cisplatin-sensitivity to resistant ovarian tumour cells with elevated wild-type p53,”Proc. Am. Assoc. Cancer Res., 34:355, Abstract #2116, 1993.
Cai et al., “Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer,”Hum. Gene Ther., 4:617-24, 1993.
Capecchi, “Altering the genome by homologous recombination”,Science, 244:1288-1292, 1989.
Carter et al., “Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency,”Virology, 191:473-476, 1992.
Casey et al., “Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene,”Oncogene, 6:1791-1797, 1991.
Casson et al., “p53 Gene Mutations in Barrett's Epithelium and Esophageal Cancer,”Cancer Research, 51:4495-4499, 1991.
Chang et al., “Inhibition of intratracheal lung cancer development by systemic delivery of E1A,”Oncogene, 13:1405-1412, 1996.
Chang et al., “Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy,”Arch Otolaryngol Head Neck Surg., 123:507-512, 1997.
Chen et al., “Expression of Wild-Type p53 in Human A673 Cells Suppresses Tumorigenicity but Not Growth Rate,”Oncogene, 6:1799-1805, 1991.
Chen et al., “Genetic Mechanisms of Tumor Suppression by the Human p53 Gene,”Science, 250:1576-1580, 1990.
Cheng et al., “Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene,”Cancer Res., 52:222-226, 1992.
Clarke, et al, “Thymocyte Apoptosis Induced by p53-Dependent and Independent Pathways,”Nature, 362:849-852, Apr. 29, 1993.
Coleman et al., “Radiation and chemotherapy sensitizers and protectors”,Critical Reviews In Oncology/Hematology, 10(Issue 3):225-252, 1990.
Colicos et al., Construction of a recombinant adenovirus containing the denV gene from bacteriophase T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts,Carcinogenesis, 12(2):249-255, 1991.
Comings, “A general theory of carcinogenesis,”Proc. Natl. Acad. Sci. USA, 70(12-Part I):3324-3328, 1973.
Conroy, “New Gene Therapy Cleared for Use Against Lung Cancer,”Biotech Daily, pp. 3-4, Sep. 18, 1992.
Copies of slides from presentation by Jack A. Roth on Sep. 19, 1996.
Culver et al., “Gene Therapy for Cancer,”TIG, 10(5):174-178, 1994.
Culver, et al, “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, 256:1550-1552, 1992.
Curiel et al., “High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes,”Human Gene Therapy, 3:147-154, 1992.
Davidson et al., “A model system for in vivo gene transfer into the central nervous system using adenoviral vector,”Nature Genetics, 3:219-223, 1993.
Debus et al.,J. Cancer Res. Clin. Oncol., 116(Suppl Part 1):5-162, Abstract #A2.037.09, 1990.
Delauncy et al., “A Stable Bifunctional Antisense Transcript Inhibiting Gene Expression in Transgenic Plants,”Proc. Natl. Acad. Sci. USA, 85:4300-4304, 1988.
Diller et al., “p53 Functions as a Cell Cycle Control Protein in Osteosarcomas,”Molecular and Cellular Biology, 10(11):5772-5781, Nov. 1990.
Donehower, “Tumor suppressor gene p53 and apoptosis,”Cancer Bull., 46(2):161-166, 1994.
Dorigo et al., “Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function,”J. Neurosurg., 88:535-540, 1998.
Eaves et al., “The biology of normal and neoplastic stem cells in CML,” Chronic Myeloid Leukemia, 2ndInt'l Conference, Bologna, Italy, Oct. 4-7, 1992. FromLeukemi

Affiliated with

Also associated with

Rating

Recombinant P53 adenovirus methods and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant P53 adenovirus methods and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant P53 adenovirus methods and compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3546688